Latest Headlines

Latest Headlines

FDA approves Dendreon's breakthrough cancer vaccine Provenge

The FDA has approved Dendreon's Provenge, a breakthrough cancer vaccine that promises to extend the lives of prostate cancer victims by several months. Widely seen as a likely blockbuster with a cost

Dendreon plays waiting game as Provenge deadline looms

Sometime by the end of tomorrow, the FDA should deliver its final decision on Dendreon's (NASDAQ: DNDN) Provenge, a potential breakthrough therapeutic cancer vaccine. (The official deadline is on

Biotech watchers on high alert for Provenge decision

Just about every biotech analyst on the planet knows that the FDA is facing a May 1 deadline for a decision on Dendreon's Provenge. As that's a Saturday, we're likely to hear about a final decision

Sanofi exec, Novartis pipeline snag vaccine awards

CHANTILLY, VA- This week saw attendees gather just outside Washington, D.C. for the 2010 World Vaccines Congress to discuss the latest in the vaccine world. Although some attendees couldn't attend

Former Genentech CEO Levinson joins Amyris' board

> AVI BioPharma's board has appointed CFO J. David Boyle II as interim president and CEO. The appointment follows former CEO and director Leslie Hudson's resignation. The board plans to initiate a

How much is too much to pay for Provenge?

With Dendreon's hotly anticipated prostate cancer drug Provenge on the doorstep of FDA approval, the company now must answer a tough question: How much can they charge for a drug that extends

A blockbuster FDA deadline looms and Dendreon shares turn red-hot

With the FDA's deadline on a final decision regarding Dendreon's Provenge less than a month away, investors have made the Seattle-based biotech's stock one of this month's hottest plays. Earlier

Dendreon tripling workforce ahead of expected vax launch

Over the years Seattle-based Dendreon made a global name for itself as it developed one of the world's first therapeutic vaccines. It's also advanced the careers of scores of biotech executives who

Dendreon shares gyrate on Provenge panel rumor

Shares of Dendreon sank 5 percent in pre-market trading after investors got word of a note from Elliot Favus of Favus Institutional Research claiming that his firm had been in contact with physicians

CEOs turn out in NY to talk up new deals for a new year

NEW YORK- Biotech CEOs go to BIO's annual CEO & Investor confab at the Waldorf-Astoria to burnish the reputations of their companies in the heart of the world's financial center. And a lineup of